Encouraging preliminary data from Curasight’s phase I glioblastoma trial are helping to shape the next stage of development. The company has submitted a protocol amendment designed to strengthen the clinical data set and generate additional information to inform future studies. A directed share issue of approximately DKK 20 million funds the path to that readout. BioStock contacted CEO Ulrich Krasilnikoff for a comment.

Read the full interview at biostock.se:

Curasight: Letting the data guide uTREAT development

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital. 

© Modular Finance, source Nordic Press Releases